A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)

PHASE3RecruitingINTERVENTIONAL
Enrollment

450

Participants

Timeline

Start Date

July 8, 2025

Primary Completion Date

May 31, 2027

Study Completion Date

July 31, 2027

Conditions
Major Depressive Disorder
Interventions
DRUG

Azetukalner

Azetukalner 20 mg taken orally once a day with food (with the evening meal when possible) for 6 weeks

DRUG

Placebo

Placebo taken orally once a day with food (with the evening meal when possible) for 6 weeks

Trial Locations (16)

10017

RECRUITING

Fieve Clinical Research, Inc., New York

27511

RECRUITING

Magnolia Clinical Research, Llc, Cary

30329

RECRUITING

Delricht Research, Atlanta

33578

RECRUITING

Equipath Health and Research Tampa Bay, Llc, Riverview

33912

RECRUITING

Gulfcoast Clinical Research Center, Fort Myers

36303

RECRUITING

Harmonex Neuroscience Research, Dothan

60462

RECRUITING

Advanced Quality Medical Research, Orland Park

63304

RECRUITING

St. Charles Psychiatric Associates - Midwest Research Group, Saint Charles

63368

RECRUITING

Psychiatric Care and Research Center, O'Fallon

73116

RECRUITING

Sooner Clinical Research, Oklahoma City

78737

RECRUITING

Austin Clinical Trial Partners, Austin

91403

RECRUITING

California Neuroscience Research, Sherman Oaks

21208-6605

RECRUITING

Pharmasite Research Inc., Baltimore

01844

RECRUITING

Activmed Practices & Research, Llc - Methuen, Methuen

08002

RECRUITING

Center for Emotional Fitness, Cherry Hill

08755

RECRUITING

Bio Behavioral Health, Toms River

All Listed Sponsors
lead

Xenon Pharmaceuticals Inc.

INDUSTRY

NCT07076407 - A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) | Biotech Hunter | Biotech Hunter